Phillips & Cohen Evidentiary Data Scientist George Collins

Affiliates of Kaiser Permanente, one of the nation’s largest integrated healthcare systems, reached a landmark agreement last month to pay $581 million to the federal government. This substantial settlement resolves multiple whistleblower lawsuits alleging that the companies engaged in widespread “risk adjustment” fraud and other forms of misconduct within their Medicare Advantage programs. The resolution highlights the persistent challenges of healthcare fraud and the indispensable role of whistleblowers and advanced data analysis in safeguarding taxpayer funds and ensuring the integrity of vital public health programs.

Introduction to the Settlement and Allegations

The $581 million settlement addresses claims that Kaiser Permanente, through various affiliated entities, systematically inflated diagnostic codes for Medicare Advantage beneficiaries. This practice, often referred to as "upcoding," allowed the healthcare giant to receive higher payments from the Centers for Medicare & Medicaid Services (CMS) than it was legitimately entitled to. The allegations, brought forth under the qui tam provisions of the federal False Claims Act (FCA), painted a picture of a sophisticated scheme that allegedly prioritized financial gain over accurate reporting, diverting funds intended for patient care.

One of the pivotal lawsuits leading to this settlement was filed in 2014 by Phillips & Cohen LLP on behalf of a whistleblower client. George Collins, senior counsel and evidentiary data scientist with Phillips & Cohen, emphasized the broader significance of the outcome. "This remarkable outcome highlights the scope and significance of health care fraud and the importance of whistleblowers in recovering money that should be going to patient care and affordability instead of the pockets of health care companies," Collins stated. His comments underscore the dual impact of such settlements: penalizing fraudulent activity and redirecting resources back to their intended purpose within the healthcare ecosystem.

Understanding Medicare Advantage and the Mechanics of Risk Adjustment Fraud

To fully grasp the nature of the fraud alleged against Kaiser Permanente, it is crucial to understand the structure of the Medicare Advantage (MA) program and its "risk adjustment" payment model. Medicare Advantage, also known as Medicare Part C, allows private insurance companies to offer Medicare benefits. These plans contract with CMS to provide healthcare services to enrolled beneficiaries, acting as an alternative to original Medicare. The popularity of MA plans has surged in recent years, with over 30 million Americans now enrolled, accounting for more than half of all eligible Medicare beneficiaries. This growth has intensified scrutiny on the financial practices of MA organizations.

Under the MA program, the government pays Medicare Advantage plans a monthly capitated fee for each enrolled member. This fee is not static; it is "risk-adjusted" based on a beneficiary’s health status, age, gender, and other demographic factors. The underlying principle of risk adjustment is to provide higher payments for sicker, more complex patients who are expected to incur greater healthcare costs, and lower payments for healthier individuals. This system aims to prevent plans from selectively enrolling healthier members ("cherry-picking") and to ensure they are adequately compensated for caring for high-need populations.

The payments are primarily determined by diagnostic codes submitted by the health plans. These codes, based on medical encounters and diagnoses made by healthcare providers, are used to calculate a "risk score" for each patient. When beneficiaries are diagnosed with certain serious or chronic health conditions—such as active cancer, diabetes with complications, or severe heart disease—their risk scores increase, leading to higher government payments to their insurers.

The core of the alleged fraud lies in the manipulation of these diagnostic codes. The Phillips & Cohen lawsuit specifically identified multiple categories of diagnosis codes that consistently exhibited extremely high error rates within Kaiser Permanente’s submissions. For instance, the complaint alleged that patients with a prior history of cancer were frequently miscoded as having active cancer. Such mischaracterizations, even if seemingly minor on an individual level, collectively led the government to make significantly higher payments to the defendants than what was medically warranted. The complaint further alleged that Kaiser Permanente affiliates failed to take appropriate corrective action, which would have necessitated refunding prior overpayments and foregoing future inflated revenues, indicating a systemic issue rather than isolated errors.

The Whistleblower Mechanism: A Critical Line of Defense

The Kaiser Permanente settlement is a potent reminder of the critical role whistleblowers play in uncovering fraud against government programs. The False Claims Act, originally enacted during the Civil War to combat fraudulent wartime contractors, empowers private citizens (known as "relators") with firsthand knowledge of fraud to file lawsuits on behalf of the government. If the government intervenes and successfully recovers funds, the whistleblower is entitled to a share of the recovery, typically ranging from 15% to 30%. This qui tam provision incentivizes individuals to come forward with information that might otherwise remain hidden, acting as a powerful deterrent against corporate misconduct.

Whistleblowers in these complex healthcare fraud cases often possess unique insights into internal company practices, data systems, and decision-making processes. Their courage to report wrongdoing, often at significant personal and professional risk, is invaluable in cases where fraud is embedded within intricate billing and coding systems. The FCA also includes provisions to protect whistleblowers from retaliation, further encouraging transparency and accountability.

Chronology of the Kaiser Case and Broader Context

While the public announcement of the settlement occurred last month, the genesis of the legal action dates back over a decade.

• 2014: Phillips & Cohen LLP files one of the key whistleblower lawsuits under the qui tam provisions of the False Claims Act. This marks the beginning of a long and complex investigative process.
• 2014-Present: Over the subsequent years, the Department of Justice, in collaboration with the whistleblower’s legal team, conducts an extensive investigation. This period involves reviewing vast amounts of Kaiser Permanente’s internal data, medical records, billing submissions, and other evidence to substantiate the allegations of fraud. The government’s decision to intervene in a qui tam case significantly strengthens its legal position and resource allocation.
• Last Month (as per original article): The federal government announces the $581 million settlement with Kaiser Permanente affiliates, resolving the multiple whistleblower cases related to risk adjustment fraud.

This settlement occurs within a broader context of increasing federal scrutiny on Medicare Advantage plans. Over the past decade, the Department of Justice and CMS have intensified efforts to combat fraud and abuse in MA, resulting in numerous enforcement actions and significant recoveries. The complexity of the risk adjustment model, coupled with the sheer volume of data involved, makes MA a particularly vulnerable area for fraud. This Kaiser settlement sends a clear message to the entire MA industry about the government’s commitment to program integrity.

The Role of Data Science in Uncovering Fraud: George Collins’ Expertise

The nature of risk adjustment fraud, which relies heavily on the manipulation of diagnostic codes within vast datasets, makes the expertise of individuals like George Collins particularly critical. Collins, described as an "evidentiary data scientist," embodies a new breed of legal professional essential for navigating the complexities of modern corporate crime. His practice at Phillips & Cohen is uniquely focused on "data-centric" cases, where large, intricate datasets provide the primary evidence of fraud, and "software-centric" cases, where software is either the instrument or the subject of the misconduct.

Collins’ background is deeply rooted in computer programming, algorithms, and data analytics. He is fluent in multiple programming languages and employs diverse analytical methods, including machine learning, natural language processing (NLP), and complex systems modeling. This specialized skill set allows him to address the formidable challenges that arise at every stage of a case, from initial investigation to litigation.

In an interview with Corporate Crime Reporter, Collins elaborated on his unique role. "My background is fairly deep into computer programming, algorithms, data analytics," he explained. "That puts me on a lot of our technical cases – cases related to fraud effectuated by computers or people using computers." He noted that the majority of his practice is in healthcare, but also extends to government contracting, customs, and high-frequency trading – all sectors where massive datasets are central to uncovering fraud.

Collins’ work is distinct from traditional e-discovery, which often involves sifting through warehouses of unstructured documents like emails. Instead, he specializes in analyzing "structured data"—billions of lines of information that could represent an entire company’s internal database, years of point-of-sale transactions, or comprehensive supply chain records. "That lands on us and we often don’t have any documentation. We are not sure if the production is complete. And I specialize in going in and working with that evidence the same way an e-discovery specialist works with ten million emails," Collins stated. His ability to rapidly process and interpret such enormous volumes of data internally gives Phillips & Cohen a significant advantage in building robust cases.

Regarding artificial intelligence, Collins adopts a pragmatic, "crotchety old fashioned view." While he extensively utilizes machine learning—which he describes as "an outgrowth of classical statistics applied to computation at scale"—he expresses reservations about generative AI for his specific work. He clarifies that his focus is on writing extremely precise code to identify specific patterns of fraud within structured data, a task where the "generative part of generative AI," which produces convincing text or images, is not directly applicable. His approach prioritizes precision and structured analysis over the more speculative applications of nascent AI technologies.

Collins’ track record speaks to the effectiveness of his data-driven approach. In 2024, he played a crucial role in securing a $90 million settlement against Humana, Inc. for allegedly submitting fraudulent bids to operate a Medicare Part D plan. He also helped achieve a $108.75 million settlement with KBR for allegedly defrauding the United States Army in connection with contracts to supply troops during the Iraq War. These cases highlight the versatility of his expertise across different forms of government fraud.

Broader Implications for Healthcare and Government Programs

The Kaiser Permanente settlement carries significant implications for the healthcare industry, government oversight, and the ongoing battle against fraud.

Financial Impact and Deterrence: The $581 million recovery is substantial, but it must be viewed in the context of the estimated total cost of healthcare fraud in the U.S. Experts like Harvard professor Malcolm Sparrow have estimated annual losses from healthcare fraud to be between $100 billion and $500 billion. Collins affirms that such figures are "absolutely possible" or even higher, underscoring that even large settlements might represent "scraping off the top of a giant iceberg." Nevertheless, Collins believes these cases have a definite deterrent impact. "Whole areas of fraud have been largely stamped out or at least it’s made it much harder to convince a group of people in a company to move forward with it," he noted, indicating that some practices become too risky for companies to pursue.

Program Integrity for Medicare Advantage: The settlement reinforces CMS’s commitment to ensuring the integrity of the Medicare Advantage program. By penalizing fraudulent upcoding, the government signals that it will vigorously protect taxpayer funds intended for the care of elderly and disabled beneficiaries. This action serves as a warning to other MA organizations to review their coding and billing practices to ensure accuracy and compliance.

The Enduring Challenge of Healthcare Fraud: Despite enforcement efforts, healthcare fraud remains a pervasive and evolving challenge. As older schemes are deterred, new ones may emerge. The complexity of the U.S. healthcare system, coupled with the vast sums of money involved, creates fertile ground for fraudulent activities. The ongoing need for robust regulatory oversight, combined with the vigilance of whistleblowers and the analytical capabilities of legal and investigative teams, will be crucial in mitigating these losses.

The Future of Fraud Detection and Prevention: The Kaiser Permanente case, and particularly the involvement of an evidentiary data scientist like George Collins, points towards the increasing reliance on advanced data analytics in fraud detection. As companies leverage sophisticated algorithms and massive databases, so too must those tasked with oversight and enforcement. The ability to process, analyze, and interpret billions of lines of structured data will become an even more indispensable tool in the fight against complex financial fraud across various sectors.

Whistleblower Profile and Government Engagement:

The success of qui tam cases often hinges on the quality of the whistleblower. Collins described ideal whistleblowers as those with insight into internal company decisions, awareness of concerns regarding legality, and knowledge of attempts to override questionable practices. He also noted that while documents are helpful, whistleblowers often come forward with just their knowledge. Crucially, he advises that whistleblowers should only bring forward data they obtained in the ordinary course of their work, emphasizing ethical conduct. Beyond the stereotypical "disgruntled employee," many whistleblowers are motivated by a belief in their company’s mission and a desire to see it operate ethically, expressing sentiments like, "Why is the company acting this way when it could be doing good for the world?"

Even when the government declines to formally intervene in a False Claims Act case, it does not necessarily indicate a lack of merit. Collins explained that declination can stem from various reasons, including resource limitations or confidence in the relator firm’s ability to prosecute the case. In such scenarios, the government often remains closely involved, as its interests are still at stake. There are instances where the government considers intervening later or maintains a collaborative relationship, underscoring that a declination is not a dismissal of the allegations’ seriousness.

In conclusion, the Kaiser Permanente settlement represents a significant victory in the ongoing effort to combat healthcare fraud. It not only recovers substantial funds for taxpayers but also reinforces the vital role of whistleblowers and specialized legal expertise in maintaining accountability within the complex landscape of government healthcare programs. The case serves as a powerful testament to the fact that sophisticated data analysis, coupled with unwavering ethical commitment, is increasingly at the forefront of protecting public resources from corporate misconduct.